160 related articles for article (PubMed ID: 35205788)
1. Real-World Time on Treatment with First-Line Pembrolizumab Monotherapy for Advanced NSCLC with PD-L1 Expression ≥ 50%: 3-Year Follow-Up Data.
Velcheti V; Hu X; Li Y; El-Osta H; Pietanza MC; Burke T
Cancers (Basel); 2022 Feb; 14(4):. PubMed ID: 35205788
[TBL] [Abstract][Full Text] [Related]
2. Pembrolizumab-combination therapy for previously untreated metastatic nonsquamous NSCLC: Real-world outcomes at US oncology practices.
Liu SV; Hu X; Li Y; Zhao B; Burke T; Velcheti V
Front Oncol; 2022; 12():999343. PubMed ID: 36324586
[TBL] [Abstract][Full Text] [Related]
3. Long-Term Real-World Outcomes of First-Line Pembrolizumab Monotherapy for Metastatic Non-Small Cell Lung Cancer With ≥50% Expression of Programmed Cell Death-Ligand 1.
Velcheti V; Hu X; Yang L; Pietanza MC; Burke T
Front Oncol; 2022; 12():834761. PubMed ID: 35402266
[TBL] [Abstract][Full Text] [Related]
4. First-line pembrolizumab monotherapy for metastatic PD-L1-positive NSCLC: real-world analysis of time on treatment.
Velcheti V; Chandwani S; Chen X; Pietanza MC; Burke T
Immunotherapy; 2019 Jul; 11(10):889-901. PubMed ID: 31181973
[No Abstract] [Full Text] [Related]
5. Pembrolizumab for Previously Treated, PD-L1-expressing Advanced NSCLC: Real-world Time on Treatment and Overall Survival.
Velcheti V; Chandwani S; Chen X; Piperdi B; Burke T
Clin Lung Cancer; 2020 Sep; 21(5):e445-e455. PubMed ID: 32376116
[TBL] [Abstract][Full Text] [Related]
6. First-Line Pembrolizumab Plus Chemotherapy for Advanced Squamous NSCLC: Real-World Outcomes at U.S. Oncology Practices.
Liu SV; Rai P; Wang D; Hu X; Schwarzenberger PO
JTO Clin Res Rep; 2023 Feb; 4(2):100444. PubMed ID: 36755804
[TBL] [Abstract][Full Text] [Related]
7. 5-Year Real-World Outcomes With Frontline Pembrolizumab Monotherapy in PD-L1 Expression ≥ 50% Advanced NSCLC.
Velcheti V; Rai P; Kao YH; Chirovsky D; Nunes AT; Liu SV
Clin Lung Cancer; 2024 May; ():. PubMed ID: 38880664
[TBL] [Abstract][Full Text] [Related]
8. Real-world outcomes of first-line pembrolizumab plus pemetrexed-carboplatin for metastatic nonsquamous NSCLC at US oncology practices.
Velcheti V; Hu X; Piperdi B; Burke T
Sci Rep; 2021 Apr; 11(1):9222. PubMed ID: 33911121
[TBL] [Abstract][Full Text] [Related]
9. Real-World Treatment Patterns and Outcomes of First-Line Immunotherapy Among Patients With Advanced Nonsquamous NSCLC Harboring
Garassino MC; Oskar S; Arunachalam A; Zu K; Kao YH; Chen C; Meng W; Pietanza MC; Zhao B; Aggarwal H
JTO Clin Res Rep; 2023 Oct; 4(10):100568. PubMed ID: 37744307
[TBL] [Abstract][Full Text] [Related]
10. First-Line Pembrolizumab Monotherapy for Advanced NSCLC With Programmed Death-Ligand 1 Expression Greater Than or Equal to 50%: Real-World Study Including Older Patients in Japan.
Goto Y; Tamura A; Matsumoto H; Isobe K; Ozaki T; Santorelli ML; Taniguchi K; Kamitani T; Irisawa M; Kanda K; Abe M; Burke T; Nokihara H
JTO Clin Res Rep; 2022 Sep; 3(9):100397. PubMed ID: 36065450
[TBL] [Abstract][Full Text] [Related]
11. Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD-L1-positive locally advanced or metastatic non-small-cell lung cancer: KEYNOTE-042 China Study.
Wu YL; Zhang L; Fan Y; Zhou J; Zhang L; Zhou Q; Li W; Hu C; Chen G; Zhang X; Zhou C; Dang T; Sadowski S; Kush DA; Zhou Y; Li B; Mok T
Int J Cancer; 2021 May; 148(9):2313-2320. PubMed ID: 33231285
[TBL] [Abstract][Full Text] [Related]
12. Real-world treatment patterns and outcomes among individuals receiving first-line pembrolizumab therapy for recurrent/metastatic head and neck squamous cell carcinoma.
Black CM; Hanna GJ; Wang L; Ramakrishnan K; Goto D; Turzhitsky V; Hair GM
Front Oncol; 2023; 13():1160144. PubMed ID: 37284189
[TBL] [Abstract][Full Text] [Related]
13. Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.
Borghaei H; Langer CJ; Paz-Ares L; Rodríguez-Abreu D; Halmos B; Garassino MC; Houghton B; Kurata T; Cheng Y; Lin J; Pietanza MC; Piperdi B; Gadgeel SM
Cancer; 2020 Nov; 126(22):4867-4877. PubMed ID: 32914866
[TBL] [Abstract][Full Text] [Related]
14. Association of Performance Status With Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy.
Sehgal K; Gill RR; Widick P; Bindal P; McDonald DC; Shea M; Rangachari D; Costa DB
JAMA Netw Open; 2021 Feb; 4(2):e2037120. PubMed ID: 33570575
[TBL] [Abstract][Full Text] [Related]
15. Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study.
Cortellini A; Cannita K; Tiseo M; Cortinovis DL; Aerts JGJV; Baldessari C; Giusti R; Ferrara MG; D'Argento E; Grossi F; Guida A; Berardi R; Morabito A; Genova C; Antonuzzo L; Mazzoni F; De Toma A; Signorelli D; Gelibter A; Targato G; Rastelli F; Chiari R; Rocco D; Gori S; De Tursi M; Mansueto G; Zoratto F; Filetti M; Bracarda S; Citarella F; Russano M; Cantini L; Nigro O; Buti S; Minuti G; Landi L; Ricciardi S; Migliorino MR; Natalizio S; Simona C; De Filippis M; Metro G; Adamo V; Russo A; Spinelli GP; Di Maio M; Banna GL; Friedlaender A; Addeo A; Pinato DJ; Ficorella C; Porzio G
Eur J Cancer; 2021 May; 148():24-35. PubMed ID: 33721704
[TBL] [Abstract][Full Text] [Related]
16. Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non-small cell lung cancer and a poor performance status.
Alessi JV; Ricciuti B; Jiménez-Aguilar E; Hong F; Wei Z; Nishino M; Plodkowski AJ; Sawan P; Luo J; Rizvi H; Carter BW; Heymach JV; Altan M; Hellmann M; Awad M
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32753547
[TBL] [Abstract][Full Text] [Related]
17. First-line pembrolizumab for non-small cell lung cancer patients with PD-L1 ≥50% in a multicenter real-life cohort: The PEMBREIZH study.
Amrane K; Geier M; Corre R; Léna H; Léveiller G; Gadby F; Lamy R; Bizec JL; Goarant E; Robinet G; Gouva S; Quere G; Abgral R; Schick U; Bernier C; Chouaid C; Descourt R
Cancer Med; 2020 Apr; 9(7):2309-2316. PubMed ID: 32022459
[TBL] [Abstract][Full Text] [Related]
18. Overall Survival With Second-Line Pembrolizumab in Patients With Non-Small-Cell Lung Cancer: Randomized Phase III Clinical Trial Versus Propensity-Adjusted Real-World Data.
Jemielita T; Li XN; Piperdi B; Zhou W; Burke T; Chen C
JCO Clin Cancer Inform; 2021 Jan; 5():56-65. PubMed ID: 33439727
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of first-line pembrolizumab monotherapy in elderly patients (aged ≥ 75 years) with non-small cell lung cancer.
Imai H; Wasamoto S; Yamaguchi O; Suzuki K; Sugiyama T; Uchino J; Minemura H; Osaki T; Ishii H; Umeda Y; Mori K; Kotake M; Kagamu H; Morozumi N; Taniguchi H; Kasai T; Minato K; Kaira K
J Cancer Res Clin Oncol; 2020 Feb; 146(2):457-466. PubMed ID: 31853661
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001).
Tamiya M; Tamiya A; Hosoya K; Taniguchi Y; Yokoyama T; Fukuda Y; Hirano K; Matsumoto H; Kominami R; Suzuki H; Hirashima T; Uchida J; Morita M; Kanazu M; Sawa N; Kinoshita Y; Hara S; Kumagai T; Fujimoto D
Invest New Drugs; 2019 Dec; 37(6):1266-1273. PubMed ID: 31392549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
